Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.

Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K.

Scand J Gastroenterol. 2009;44(7):853-60.

PMID:
19811343
2.

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.

Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Review.

3.

Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.

Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G.

Clin Ther. 2008 Jun;30(6):1168-76. doi: 10.1016/j.clinthera.2008.06.012.

PMID:
18640473
4.

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group..

Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.

5.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network..

JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.

6.

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G.

Am J Gastroenterol. 2005 May;100(5):1082-90.

PMID:
15842582
7.

[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].

Zhang DM, Zhang GY, Wang T, Zhong HJ, Chen WK.

Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1279-83. Chinese.

PMID:
16796890
8.

Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.

Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M.

Metabolism. 2011 Sep;60(9):1278-84. doi: 10.1016/j.metabol.2011.01.011. Epub 2011 Mar 15.

PMID:
21411114
9.

Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A.

Hepatogastroenterology. 2012 Oct;59(119):2099-2103. doi: 10.5754/hge10860.

PMID:
23234816
10.

Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D.

Cardiovasc Diabetol. 2012 Jun 7;11:61. doi: 10.1186/1475-2840-11-61.

11.

Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.

Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K.

Pediatr Diabetes. 2009 Feb;10(1):5-13. doi: 10.1111/j.1399-5448.2008.00450.x. Epub 2008 Aug 20.

PMID:
18721166
12.

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH.

Aliment Pharmacol Ther. 2009 Jan;29(2):172-82. doi: 10.1111/j.1365-2036.2008.03869.x. Epub 2008 Oct 9.

13.
14.

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. Review.

PMID:
17253544
15.

Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.

Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, Baptista T.

Schizophr Res. 2009 Aug;113(1):19-26. doi: 10.1016/j.schres.2009.05.007. Epub 2009 Jun 9. Erratum in: Schizophr Res. 2009 Nov;115(1):96.

PMID:
19515536
16.

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.

Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R.

Clin Gastroenterol Hepatol. 2006 May;4(5):639-44. Epub 2006 Apr 17.

PMID:
16630771
17.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
18.

Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease.

Sofer E, Shargorodsky M.

Hepatol Int. 2016 Jan;10(1):169-74. doi: 10.1007/s12072-015-9649-6. Epub 2015 Jul 22.

PMID:
26198758
19.

Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial.

Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL.

J Gastroenterol Hepatol. 2013 Jan;28(1):57-62. doi: 10.1111/j.1440-1746.2012.07286.x.

PMID:
23034128
20.

Supplemental Content

Support Center